About Benitec Biopharma Inc.
https://benitec.comBenitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions.
CEO
Jerel A. Banks
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-07-26 | Reverse | 1:17 |
| 2020-04-15 | Reverse | 2:3 |
ETFs Holding This Stock
Summary
Showing Top 3 of 44
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Oppenheimer
Outperform
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
SUVRETTA CAPITAL MANAGEMENT, LLC
Shares:9.88M
Value:$119.8M
JANUS HENDERSON GROUP PLC
Shares:2.91M
Value:$35.32M
FRANKLIN RESOURCES INC
Shares:2.59M
Value:$31.41M
Summary
Showing Top 3 of 60
About Benitec Biopharma Inc.
https://benitec.comBenitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $0 ▼ | $14.65M ▼ | $-13.56M ▲ | 0% ▲ | $-0.22 ▲ | $-13.38M ▲ |
| Q4-2025 | $556K ▲ | $17.45M ▲ | $-16.15M ▼ | -2.9K% ▼ | $-0.39 ▼ | $-19.02M ▼ |
| Q3-2025 | $0 | $10.08M ▲ | $-9.35M ▼ | 0% | $-0.24 ▲ | $-9.25M ▼ |
| Q2-2025 | $0 | $8.53M ▲ | $-7.36M ▼ | 0% | $-0.33 ▲ | $-7.28M ▼ |
| Q1-2025 | $0 | $5.7M | $-5.06M | 0% | $-0.48 | $-4.97M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $94.48M ▼ | $96.03M ▼ | $2.43M ▲ | $93.6M ▼ |
| Q4-2025 | $97.74M ▼ | $99.59M ▼ | $2.3M ▼ | $97.3M ▼ |
| Q3-2025 | $103.58M ▲ | $105.21M ▲ | $7.64M ▲ | $97.57M ▲ |
| Q2-2025 | $78.28M ▲ | $79.07M ▲ | $3.13M ▼ | $75.94M ▲ |
| Q1-2025 | $67.84M | $68.77M | $4.59M | $64.18M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $-8.96M ▼ | $-3.35M ▲ | $0 ▲ | $0 ▼ | $-3.27M ▲ | $-3.35M ▲ |
| Q4-2025 | $-8.8M ▲ | $-8.53M ▼ | $-466.44 ▲ | $4.28M ▼ | $-5.79M ▼ | $-8.53M ▼ |
| Q3-2025 | $-9.35M ▼ | $-3.09M ▲ | $-6K ▲ | $28.41M ▲ | $25.3M ▲ | $-3.09M ▲ |
| Q2-2025 | $-7.36M ▼ | $-7.7M ▼ | $-12K ▼ | $17.87M ▼ | $10.44M ▼ | $-7.71M ▼ |
| Q1-2025 | $-5.06M | $-4.59M | $0 | $21.66M | $16.98M | $-4.59M |
Revenue by Products
| Product | Q1-2021 | Q3-2021 | Q2-2021 |
|---|---|---|---|
 License | $0 ▲ | $0 ▲ | $0 ▲ |
 Royalty | $0 ▲ | $0 ▲ | $0 ▲ |
 Service | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Jerel A. Banks
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-07-26 | Reverse | 1:17 |
| 2020-04-15 | Reverse | 2:3 |
ETFs Holding This Stock
Summary
Showing Top 3 of 44
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Oppenheimer
Outperform
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
SUVRETTA CAPITAL MANAGEMENT, LLC
Shares:9.88M
Value:$119.8M
JANUS HENDERSON GROUP PLC
Shares:2.91M
Value:$35.32M
FRANKLIN RESOURCES INC
Shares:2.59M
Value:$31.41M
Summary
Showing Top 3 of 60